Literature DB >> 33313770

Surgical management of Ebstein anomaly: impact of the adult congenital heart disease anatomical and physiological classifications.

Laura Homzova1, Joachim Photiadis1, Nicodème Sinzobahamvya1, Stanislav Ovroutski2, Mi-Young Cho1, Antonia Schulz1.   

Abstract

OBJECTIVES: Our goal was to evaluate the impact of the adult congenital heart disease anatomical and physiological (ACHD AP) classification system on the surgical management of Ebstein anomaly (EA) in adult patients.
METHODS: From February 2000 through August 2017, data of patients aged at least 16 years, who underwent primary EA surgery, were retrospectively evaluated. The cohort was divided in 2 groups according to their ACHD AP classification: the moderate EA group (IIB, IIC) and the severe EA group (IID). Survival, freedom from reoperation and freedom from occurrence of major adverse advents were estimated.
RESULTS: There were 33 patients (21 women, 12 men). Eighteen belonged to the moderate group, 15 to the severe group. There were 12 female patients (80%) in the severe group. Patients in the moderate group were younger than those in the severe group (P = 0.02): 32 ± 12 vs 44 ± 15 years old. Thirty tricuspid valve repairs and 3 replacements were performed. Repair was mainly performed in the moderate group (P = 0.02). Overall survival was 90.1 ± 5.4% at 9 months after the operation and did not change in the later follow-up period. It was 100% for patients in the moderate group and 80.0 ± 10.3% in the severe group (P = 0.07), and 75.0 ± 12.5% for female patients of in the severe group compared to 100% for the remaining patients (P = 0.025). Survival free from major adverse events, including reoperation, at 10 years was 60.0 ± 12.6% in the moderate and 38.1% ± 12.9% in the severe group (P = 0.03). No patient in the moderate group evolved to be in the severe group at late follow-up.
CONCLUSION: Adult EA patients should undergo surgery earlier when they are still in the moderate ACHD AP classification.
© The Author(s) 2020. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Adult congenital heart disease; Adult congenital heart disease anatomical and physiological classification; Adult congenital heart disease surgery; Ebstein anomaly; Operative outcomes

Mesh:

Year:  2021        PMID: 33313770      PMCID: PMC8906756          DOI: 10.1093/icvts/ivaa294

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  13 in total

Review 1.  Preoperative Physiology, Imaging, and Management of Ebstein's Anomaly of the Tricuspid Valve.

Authors:  Brian Morray
Journal:  Semin Cardiothorac Vasc Anesth       Date:  2015-11-29

2.  2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Karen K Stout; Curt J Daniels; Jamil A Aboulhosn; Biykem Bozkurt; Craig S Broberg; Jack M Colman; Stephen R Crumb; Joseph A Dearani; Stephanie Fuller; Michelle Gurvitz; Paul Khairy; Michael J Landzberg; Arwa Saidi; Anne Marie Valente; George F Van Hare
Journal:  J Am Coll Cardiol       Date:  2018-08-16       Impact factor: 24.094

3.  Quality measures for congenital and pediatric cardiac surgery.

Authors:  Jeffrey Phillip Jacobs; Marshall Lewis Jacobs; Erle H Austin; Constantine Mavroudis; Sara K Pasquali; Francois G Lacour-Gayet; Christo I Tchervenkov; Hal Walters; Emile A Bacha; Pedro J Del Nido; Charles D Fraser; J William Gaynor; Jennifer C Hirsch; David L S Morales; Kamal K Pourmoghadam; James S Tweddell; Richard L Prager; John E Mayer
Journal:  World J Pediatr Congenit Heart Surg       Date:  2012-01-01

4.  Improving Results of Surgery for Ebstein Anomaly: Where Are We After 235 Cone Repairs?

Authors:  Kimberly A Holst; Joseph A Dearani; Sameh Said; Roxann B Pike; Heidi M Connolly; Bryan C Cannon; Kristen L Sessions; Megan M O'Byrne; Patrick W O'Leary
Journal:  Ann Thorac Surg       Date:  2017-11-24       Impact factor: 4.330

5.  Ebstein's anomaly: presentation and outcome from fetus to adult.

Authors:  D S Celermajer; C Bull; J A Till; S Cullen; V P Vassillikos; I D Sullivan; L Allan; P Nihoyannopoulos; J Somerville; J E Deanfield
Journal:  J Am Coll Cardiol       Date:  1994-01       Impact factor: 24.094

6.  Outcome of cardiac surgery in patients 50 years of age or older with Ebstein anomaly: survival and functional improvement.

Authors:  Christine H Attenhofer Jost; Heidi M Connolly; Christopher G Scott; Harold M Burkhart; Carole A Warnes; Joseph A Dearani
Journal:  J Am Coll Cardiol       Date:  2012-06-05       Impact factor: 24.094

7.  The outcomes of operations for 539 patients with Ebstein anomaly.

Authors:  Morgan L Brown; Joseph A Dearani; Gordon K Danielson; Frank Cetta; Heidi M Connolly; Carole A Warnes; Zhuo Li; David O Hodge; David J Driscoll
Journal:  J Thorac Cardiovasc Surg       Date:  2008-05       Impact factor: 5.209

8.  Surgical Management and Outcomes of Ebstein Anomaly in Neonates and Infants: A Society of Thoracic Surgeons Congenital Heart Surgery Database Analysis.

Authors:  Kimberly A Holst; Joseph A Dearani; Sameh M Said; Ryan R Davies; Christian Pizarro; Christopher Knott-Craig; T K Susheel Kumar; Vaughn A Starnes; S Ram Kumar; Sara K Pasquali; Dylan P Thibault; James M Meza; Kevin D Hill; Karen Chiswell; Jeffrey P Jacobs; Marshall L Jacobs
Journal:  Ann Thorac Surg       Date:  2018-05-16       Impact factor: 4.330

9.  Adult congenital open-heart surgery: emergence of a new mortality score.

Authors:  Mi-Young Cho; Michael Weidenbach; Nicodème Sinzobahamvya; Katharina Gräfe; Peter Murin; Felix Berger; Joachim Photiadis
Journal:  Eur J Cardiothorac Surg       Date:  2020-07-01       Impact factor: 4.191

10.  A new reconstructive operation for Ebstein's anomaly of the tricuspid valve.

Authors:  A Carpentier; S Chauvaud; L Macé; J Relland; S Mihaileanu; J P Marino; B Abry; P Guibourt
Journal:  J Thorac Cardiovasc Surg       Date:  1988-07       Impact factor: 5.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.